The Latest Breaking News from Sarepta

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Sarepta is building a base as this biotech stock tries to convince regulators to approve its gene therapy.